<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01166308</url>
  </required_header>
  <id_info>
    <org_study_id>CINDERELLA</org_study_id>
    <secondary_id>2009-017352-26</secondary_id>
    <nct_id>NCT01166308</nct_id>
  </id_info>
  <brief_title>Carbon Ion Radiotherapy for Recurrent Gliomas</brief_title>
  <acronym>CINDERELLA</acronym>
  <official_title>Randomised Phase I/II Study to Evaluate Carbon Ion Radiotherapy Versus Fractionated Stereotactic Radiotherapy in Patients With Recurrent or Progressive Gliomas: The CINDERELLA Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of patients with recurrent glioma includes neurosurgical resection, chemotherapy,&#xD;
      or radiation therapy. In most cases, a full course of radiotherapy has been applied after&#xD;
      primary diagnosis, therefore application of re-irradiation has to be applied cautiously. With&#xD;
      modern precision photon techniques such as fractionated stereotactic radiotherapy (FSRT), a&#xD;
      second course of radiotherapy is safe and effective and leads to survival times of 22, 16 and&#xD;
      8 months for recurrent WHO grade II, III and IV tumors.&#xD;
&#xD;
      Carbon ions offer physical and biological characteristics. Due to their inverted dose profile&#xD;
      and the high local dose deposition within the Bragg peak precise dose application and sparing&#xD;
      of normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an&#xD;
      increase relative biological effectiveness (RBE), which can be calculated between 2 and 5&#xD;
      depending on the Glioblastoma (GBM) cell line as well as the endpoint analyzed. Protons,&#xD;
      however, offer an RBE which is comparable to photons.&#xD;
&#xD;
      First Japanese Data on the evaluation of carbon ion radiation therapy for the treatment of&#xD;
      primary high-grade gliomas showed promising results in a small and heterogeneous patient&#xD;
      collective.&#xD;
&#xD;
      In the current Phase I/II-CINDERELLA-trial re-irradiation using carbon ions will be compared&#xD;
      to FSRT applied to the area of contrast enhancement representing high-grade tumor areas in&#xD;
      patients with recurrent gliomas. Within the Phase I Part of the trial, the Recommended Dose&#xD;
      (RD) of carbon ion radiotherapy will be determined in a dose escalation scheme. In the&#xD;
      subsequent randomized Phase II part, the RD will be evaluated in the experimental arm,&#xD;
      compared to the standard arm, FSRT with a total dose of 36 Gy in single doses of 2 Gy.&#xD;
&#xD;
      Primary endpoint of the Phase I part is toxicity. Primary endpoint of the randomized part II&#xD;
      is survival after re-irradiation at 12 months, secondary endpoint is progression-free&#xD;
      survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2010</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>at 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Carbon Ion Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carbon Ion Radiotherapy in the RD determined within the Phase I Part of the Trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Treatment: Fractionated Stereotacitc Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Precision Radiotherapy performed as Fractionated Stereotactic Radiotherapy (FSRT) up to 36 Gy in single dosis of 2 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Carbon Ion Radiotherapy</intervention_name>
    <description>Carbon Ion Radiotherapy in the RD determined within the Phase I part of the Study (10 x 3Gy E to 16 x 3 Gy E)</description>
    <arm_group_label>Carbon Ion Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fractionated Stereotactic Radiotherapy (FSRT)</intervention_name>
    <description>Standard Treatment as Re-Irradiation performed as Fractionated Stereotactic Radiotherapy (FSRT)up to 36 Gy in single doses of 2 Gy</description>
    <arm_group_label>Standard Treatment: Fractionated Stereotacitc Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  unifocal, supratentorial recurrent glioma&#xD;
&#xD;
          -  contrast enhancement on T1-weighted MRI and/or Amino-Acid-PET-positive high-grade&#xD;
             tumor areas&#xD;
&#xD;
          -  indication re-irradiation&#xD;
&#xD;
          -  age ≥ 18 years of age&#xD;
&#xD;
          -  Karnofsky Performance Score ≥60&#xD;
&#xD;
          -  For women with childbearing potential, (and men) adequate contraception.&#xD;
&#xD;
          -  Ability of subject to understand character and individual consequences of the clinical&#xD;
             trial&#xD;
&#xD;
          -  Written informed consent (must be available before enrolment in the trial)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multifocal Glioma or Gliomatosis cerebri&#xD;
&#xD;
          -  refusal of the patients to take part in the study&#xD;
&#xD;
          -  previous re-irradiation or prior radiosurgery or prio treatment with interstitial&#xD;
             radioactive seeds&#xD;
&#xD;
          -  time interval of &lt; 6 months after primary radiotherapy&#xD;
&#xD;
          -  Patients who have not yet recovered from acute toxicities of prior therapies&#xD;
&#xD;
          -  Known carcinoma &lt; 5 years ago (excluding Carcinoma in situ of the cervix, basal cell&#xD;
             carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment&#xD;
             interfering with study therapy&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Participation in another clinical study or observation period of competing trials,&#xD;
             respectively.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of Heidelberg, Department of Radiation Oncology</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>July 19, 2010</study_first_submitted>
  <study_first_submitted_qc>July 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2010</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Juergen Debus</investigator_full_name>
    <investigator_title>Prof. Dr. Dr. Jürgen Debus</investigator_title>
  </responsible_party>
  <keyword>Recurrent Glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

